Indegene Ltd Share Price
As on 18 November 2025 at 23:51 IST
Net profit for the period increased 32% to ₹116 crores in Q1 FY26, from ₹88 crores in Q1 FY25. Total income for the quarter increased 12% year-on-year to ₹783 crores from ₹699 crores.
About Indegene Ltd
Indegene Ltd. is a digital-first life sciences commercialization company that provides a range of services to biopharmaceutical and medical device companies. It operates in the healthcare and technology sectors. Indegene has been a significant player since its inception in 1998. With decades of experience, the company has established itself as a trusted partner for some of the largest global biopharmaceutical companies. The headquarters of Indegene is located in Bangalore, Karnataka, India. Indegene’s main products and services include enterprise commercial solutions, medical transformation, data and analytics, product development, and omnichannel activation. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-6.36%
Over 6 Months
-15.22%
Over 1 Year
-22.07%
Over 3 Years
None%
Indegene Ltd Summary
Close ₹508.15
Open ₹511.55
High ₹515.60
Low ₹506.60
Volume 1,77,609
Net Turnover (in Cr) ₹9.06
52Wk High ₹694.40
52Wk Low ₹499
52Wk High / Low
499
694.40
Indegene Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹12,202.70
EPS (TTM) 8.71
Book Value (BV) 81.72
Div. Yield 0.39 %
P/E (TTM) 58.38
Price/Book Value 6.22
Delivery % 48.61 %
Face Value 2
Key Ratios
PE Ratio 76.39
PB Ratio 7.34
EV to Sales 12.57
PEG Ratio 3.49
ROA 9.18
ROE 12.76
Debt-Equity 0.02
Net Profit Margin 16.58
Operating Profit Margin 24.77
Indegene Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,946.50 | 2,665.90 | 2,364.10 | 1,690.50 | 996.92 |
| Total Expenses | 2,407.20 | 2,209.70 | 2,001.10 | 1,417.10 | 768.25 |
| Profit Before Tax | 539.30 | 458.60 | 363 | 226.50 | 231.46 |
| Profit After Tax | 406.70 | 336.70 | 266.10 | 162.82 | 185.68 |
| Operating Profit After Depreciation | 561.30 | 505.60 | 394.30 | 279.36 | 235.63 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 677.60 | 645.80 | 664.10 | 137.72 | 85.92 |
| Total Non Current Assets | 795.90 | 754.80 | 755.20 | 223.44 | 136.75 |
| Total Current Assets | 2,530 | 1,790.80 | 1,448.70 | 1,130.03 | 459.29 |
| Total Assets | 3,325.90 | 2,545.60 | 2,203.90 | 1,353.47 | 596.04 |
| Total Shareholder's Fund | 2,615.60 | 1,429.10 | 1,063.80 | 763.90 | 324.51 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 441.90 | 507.70 | 130.20 | 297.04 | 172.03 |
| Net Cash Used In Investing Activities | -677 | -326.50 | -896 | -157.60 | -81.03 |
| Net Cash Used In Financing Activities | 287.50 | -66.20 | 333.10 | 233.48 | -131.51 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,184 | 1,095.90 | 1,042.50 | 864.50 | 535.10 |
| Total Expenses | 945.50 | 915.30 | 865.90 | 694.60 | 381.70 |
| Profit Before Tax | 238.50 | 180.60 | 176.60 | 169.90 | 156.40 |
| Profit After Tax | 181.30 | 137.90 | 130.20 | 132.70 | 129.50 |
| Operating Profit After Depreciation | 244.70 | 187.20 | 183 | 172.90 | 156.90 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 52.80 | 56.10 | 78.30 | 72 | 40.60 |
| Total Non Current Assets | 931.70 | 469.30 | 334.80 | 315.60 | 154.70 |
| Total Current Assets | 1,218 | 751 | 702.90 | 534.50 | 217.90 |
| Total Assets | 2,149.70 | 1,220.30 | 1,037.70 | 850.10 | 372.60 |
| Total Shareholder's Fund | 1,888.20 | 953.80 | 795.30 | 650 | 253.90 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 129 | 176.20 | 81.90 | 38.20 | 53.30 |
| Net Cash Used In Investing Activities | -824.30 | -189 | -51 | -266.90 | -34.10 |
| Net Cash Used In Financing Activities | 717.30 | -15.80 | -16.90 | 244.90 | -37.10 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 804.20 | 760.80 | 755.60 | 720.40 | 686.80 |
| Total Expenses | 663.60 | 605.50 | 608.10 | 588.60 | 560.70 |
| Profit Before Tax | 133.10 | 152.10 | 149.30 | 146.30 | 124.10 |
| Profit After Tax | 102.10 | 116.40 | 117.60 | 109.70 | 91.70 |
| Operating Profit after Depreciation | 160.30 | 177.40 | 173.10 | 169.50 | 147.50 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 306.70 | 255.60 | 266.70 | 286.70 | 281.70 |
| Total Expenses | 236.10 | 218.90 | 227.10 | 234.80 | 235.30 |
| Profit Before Tax | 77.50 | 59.80 | 66.40 | 66.10 | 61 |
| Profit After Tax | 59.90 | 45.10 | 54.20 | 49.90 | 44.80 |
| Operating Profit after Depreciation | 88.10 | 68.80 | 74.80 | 74.20 | 68.80 |
Indegene Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 504.63
S2 501.12
S3 495.63
Pivot 510.12
R1 513.63
R2 519.12
R3 522.63
Moving Average
20 SMA 533.38
50 SMA 551.67
100 SMA 559.35
200 SMA 566.01
Indegene Ltd Corporate Actions
Indegene Ltd
₹2.0/Share
Announcement Date 13 Jun 2025
Record Date 13 Jun 2025
Div Yield 100%
Indegene Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Max Healthcare Institute Ltd | ₹1,121.90 | ₹1,09,099.45 |
| Apollo Hospitals Enterprise Ltd | ₹7,488.40 | ₹1,07,671.70 |
| Fortis Healthcare Ltd | ₹944.15 | ₹71,279.37 |
| Narayana Hrudayalaya Ltd | ₹2,027.90 | ₹41,442.33 |
| Aster DM Healthcare Ltd | ₹678.35 | ₹35,146.74 |
Indegene Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Invesco India Technology Fund | 2.60% |
| SBI Innovative Opportunities Fund | 1.72% |
| Sundaram Business Cycle Fund | 1.26% |
| SBI Technology Opportunities Fund | 0.98% |
| Helios Flexi Cap Fund | 0.92% |
Indegene Ltd News
Indegene to conduct board meeting
On 30 October 2025
23 Oct 2025, 05:27 pm
Indegene expands its consulting practice to support life sciences organizations
17 Oct 2025, 12:11 pm
Indegene acquires Pennsylvania-based BioPharm
To strengthen its commercialization portfolio with AdTech
01 Oct 2025, 03:15 pm
Indegene partners with Datavant to enhance clinical trial recruitment
Indegene said that it has entered into a strategic partnership with Datavant to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies.
20 Sep 2025, 03:02 pm
Indegene announces strategic partnership with Datavant
To enhance patient recruitment for clinical trials focused on rare disease
19 Sep 2025, 08:05 pm
Indegene Ltd Stock Analysis
- Annual revenue for Indegene Ltd increased by 8.04% to ₹1,184 crore in FY 2025 from ₹1,095.90 crore in FY 2024.
- Annual Net Profit for Indegene Ltd increased by 31.47% to ₹181.30 crore in FY 2025 from ₹137.90 crore in FY 2024.
- Promoter Shareholding in Indegene Ltd remains unchanged by 0.00% in the most recent quarter, from 0% in June 2025 to 0% in September 2025.
- Indegene Ltd delivered a 1-year return of -22.07% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Indegene Ltd share price moved down by 0.24% from its previous close of INR ₹508.15. The latest Indegene Ltd share price is INR ₹506.95.
- Indegene Ltd share price today has been at a low of 504.05 and a high of 509.40. Over the past 52 weeks, the Indegene Ltd share price has seen a low of 499 and a high of 694.40.
About Indegene Ltd
Indegene Ltd. is a digital-first life sciences commercialization company. It provides a range of services to biopharmaceutical and medical device companies. The company helps these enterprises develop products and bring them to market. It also helps them in growing their impact throughout the product life cycle. Indegene combines healthcare expertise with tailored technology and an agile operating model. This allows them to deliver personalized, omnichannel experiences for patients and healthcare professionals.
Indegene has been a key player in the healthcare and technology sectors since its founding in 1998. With decades of experience, the company has built a strong reputation. It is now a trusted partner for some of the largest global biopharmaceutical companies. Indegene's headquarters is located in Bangalore, Karnataka. It serves as the central hub for the company's operations and strategic initiatives.
The company does not have a promoter shareholding. However, it has a public shareholding of 92.01% in the company. It also has a team of professional managerial promoters who manage the operations of the company. They are as follows-
Indegene may not be the largest in terms of market share or market capitalization. However, it is highly regarded for its innovative solutions and customer-centric approach. The company’s stock is well-regarded in the market, reflecting its strong performance and market presence.
The registered office of Indegene Ltd. is in Bengaluru, Karnataka and the office of the registrar is in Mumbai, Maharashtra. Indegene Ltd. stands out as a major player in the healthcare and technology sectors. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward. This propels Indegene towards sustained growth and industry leadership.
One of Indegene's primary impacts is its role in transforming the commercialization process. This is particularly significant for life sciences companies. The company provides a range of services, including consulting and enterprise medical solutions. These services help clients navigate the complex landscape of product development and market entry.
Indegene’s focus on digital innovation has been a game-changer for the industry. The company leverages advanced technologies like machine learning and data analytics. These technologies enhance its service offerings. They are designed to meet the unique needs of each client.
The company’s impact extends to improving patient engagement and outcomes. Indegene’s omnichannel activation services ensure healthcare professionals receive timely and relevant information. This includes updates about new treatments and therapies. This approach enhances patient adherence to prescribed treatments and improves overall health outcomes. Additionally, Indegene’s digital platforms improve communication between patients and healthcare providers. This leads to more informed and empowered patients.
Indegene has also played a crucial role in supporting clinical trials and research. The company’s enterprise clinical solutions streamline the clinical trial process. This includes everything from patient recruitment to data management. These solutions help reduce the time and cost of bringing new therapies to market. As a result, they accelerate the availability of innovative treatments for patients.
The company’s commitment to sustainability and social responsibility further amplifies its impact. Indegene engages in various corporate social responsibility initiatives aimed at improving access to quality education and healthcare. These initiatives include partnerships with leading educational and healthcare organizations. They aim to support the missions of these organizations. Indegene’s CSR efforts reflect its dedication to making a positive difference in the communities it serves.
Indegene’s strategic collaborations and partnerships have also contributed to its impact. The company works with a range of stakeholders, including pharmaceutical companies and technology firms. These partnerships help deliver integrated solutions. These collaborations allow Indegene to leverage additional resources and expertise. This enhances its ability to tackle complex challenges in the life sciences sector.
The company’s financial performance and growth trajectory are indicative of its impact on the industry. Indegene has consistently achieved strong revenue growth, driven by its innovative solutions and customer-centric approach. The company’s ability to attract significant investments, such as the $200 million from Carlyle and Brighton Park. This highlights its potential for continued growth and its prospects for success.
Indegene’s impact is also evident in its role as a thought leader in the industry. The company regularly publishes research and insights on emerging trends and best practices in life sciences commercialization. These publications provide valuable guidance to industry stakeholders. They help them navigate the evolving landscape and make informed decisions.
Indegene has been a key player in the healthcare and technology sectors since its founding in 1998. With decades of experience, the company has built a strong reputation. It is now a trusted partner for some of the largest global biopharmaceutical companies. Indegene's headquarters is located in Bangalore, Karnataka. It serves as the central hub for the company's operations and strategic initiatives.
The company does not have a promoter shareholding. However, it has a public shareholding of 92.01% in the company. It also has a team of professional managerial promoters who manage the operations of the company. They are as follows-
- Manish Gupta
- Sanjay Suresh Parikh
- Rajesh Bhaskaran Nair
- Krishnamurthy Venugopala Tenneti
- Ashish Gupta
Indegene may not be the largest in terms of market share or market capitalization. However, it is highly regarded for its innovative solutions and customer-centric approach. The company’s stock is well-regarded in the market, reflecting its strong performance and market presence.
The registered office of Indegene Ltd. is in Bengaluru, Karnataka and the office of the registrar is in Mumbai, Maharashtra. Indegene Ltd. stands out as a major player in the healthcare and technology sectors. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward. This propels Indegene towards sustained growth and industry leadership.
The Impact of Indegene Limited
Indegene Ltd. has made a significant impact on the life sciences and healthcare sectors. This is due to its innovative digital solutions and services. Established in 1998, the company has grown significantly. It has become a trusted partner for biopharmaceutical and medical device companies. Indegene’s contributions span product development and lifecycle management. These efforts help its clients achieve better outcomes and improve patient care.One of Indegene's primary impacts is its role in transforming the commercialization process. This is particularly significant for life sciences companies. The company provides a range of services, including consulting and enterprise medical solutions. These services help clients navigate the complex landscape of product development and market entry.
Indegene’s focus on digital innovation has been a game-changer for the industry. The company leverages advanced technologies like machine learning and data analytics. These technologies enhance its service offerings. They are designed to meet the unique needs of each client.
The company’s impact extends to improving patient engagement and outcomes. Indegene’s omnichannel activation services ensure healthcare professionals receive timely and relevant information. This includes updates about new treatments and therapies. This approach enhances patient adherence to prescribed treatments and improves overall health outcomes. Additionally, Indegene’s digital platforms improve communication between patients and healthcare providers. This leads to more informed and empowered patients.
Indegene has also played a crucial role in supporting clinical trials and research. The company’s enterprise clinical solutions streamline the clinical trial process. This includes everything from patient recruitment to data management. These solutions help reduce the time and cost of bringing new therapies to market. As a result, they accelerate the availability of innovative treatments for patients.
The company’s commitment to sustainability and social responsibility further amplifies its impact. Indegene engages in various corporate social responsibility initiatives aimed at improving access to quality education and healthcare. These initiatives include partnerships with leading educational and healthcare organizations. They aim to support the missions of these organizations. Indegene’s CSR efforts reflect its dedication to making a positive difference in the communities it serves.
Indegene’s strategic collaborations and partnerships have also contributed to its impact. The company works with a range of stakeholders, including pharmaceutical companies and technology firms. These partnerships help deliver integrated solutions. These collaborations allow Indegene to leverage additional resources and expertise. This enhances its ability to tackle complex challenges in the life sciences sector.
The company’s financial performance and growth trajectory are indicative of its impact on the industry. Indegene has consistently achieved strong revenue growth, driven by its innovative solutions and customer-centric approach. The company’s ability to attract significant investments, such as the $200 million from Carlyle and Brighton Park. This highlights its potential for continued growth and its prospects for success.
Indegene’s impact is also evident in its role as a thought leader in the industry. The company regularly publishes research and insights on emerging trends and best practices in life sciences commercialization. These publications provide valuable guidance to industry stakeholders. They help them navigate the evolving landscape and make informed decisions.
FAQ’s
What is the share price of Indegene Ltd today?
Indegene Ltd share price as on 18 Nov 2025 is ₹ 506.95
What is the Market Cap of Indegene Ltd?
The market cap of Indegene Ltd stock is ₹12,202.70 Cr.
What is the PE Ratio of Indegene Ltd?
The Price to Earnings (P/E) Ratio of Indegene Ltd is 76.39
What is the PB Ratio of Indegene Ltd?
The Price to Book (P/B) Ratio of Indegene Ltd is 7.34
What is the 52 week high of Indegene Ltd Share Price?
The 52 week high of Indegene Ltd share price stands at ₹694.40
What is the 52 week low of Indegene Ltd Share Price?
The 52 week low of Indegene Ltd share price stands at ₹499
How can I buy shares of Indegene Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Indegene Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
